Risk and benefit evaluation in development of pharmaceutical products.

  title={Risk and benefit evaluation in development of pharmaceutical products.},
  author={C. S. Aaron and Philip R. Harbach and S S Mattano and J. K. Mayo and Y. Wang and R L Yu and David M. Zimmer},
  journal={Environmental Health Perspectives},
  pages={291 - 295}
Pharmaceutical products are intended to cure disease, reduce pain and suffering, prolong life, and correct metabolic deficits in patients. However, the potential patient population is intrinsically genetically heterogenous, and this factor complicates the evaluation of data on all aspects of safety evaluation of new drugs. Often the genetic heterogeneity is related to drug metabolizing capacity, but recent evidence suggests that heterogeneity in repair capacity as well as structural integrity… 
Evaluation of the cytogenetic damage induced by the antihypertensive drug nimodipine in human lymphocytes.
The differing results in vivo and in vitro could be due to extensive metabolism of nimodipine, indicating that the cytogenetic effect observed was due to the drug itself rather than its metabolites or to an adaptive response to nimmodipine in vivo.
In vitro and in vivo evaluation of the antihypertensive drug atenolol in cultured human lymphocytes: effects of long-term therapy.
The data suggest that chronic exposure to atenolol resulted mainly in the induction of chromosome loss, so an aneugenic activity could be predicted.
Genotoxic evaluation of five Angiotesin II receptor blockers: in vivo and in vitro micronucleus assay.
Benefit–risk evaluation: the past, present and future
  • J. Juhaeri
  • Business
    Therapeutic advances in drug safety
  • 2019
The past, the present, and the future, and key events that played critical roles in changing the field of benefit–risk profiles are described.
Benefit‐risk analysis: a proposal using quantitative methods
Adjustments to number‐needed‐to‐treat (NNT) analysis and a new method, minimum clinical efficacy (MCE) analysis are presented and critically discussed.
The roles of RFRP in the central control of reproduction : photoperiodic and sex-specific differences
It is demonstrated that RFRP is a key component in the seasonal control of reproduction while at the same time specifically regulating cyclic events controlling reproductive activity in females.
Therapeutic Advances in Drug Safety
  • 2019
Decision Factor Evidence and Uncertainties Conclusions and Reasons Analysis of Condition Current Treatment Options Benefit Risk Risk Management Benefit – Risk Summary Assessment
  • 2019


The quality of genotoxicity testing of drugs. Experiences of a regulatory agency with new and old compounds.
This publication gives some practical advice for judging the plausibility and relevance of published data for evaluating data for 'old compounds' regulatory authorities are confronted with considerable problems.
Role of genotoxicity assays in the regulation of chemicals in The Netherlands: considerations and experiences.
Genotoxicity testing and data interpretation as applied in The Netherlands in the context of the regulation of chemicals is discussed, such as their predictivity for carcinogenicity, the limited database concerning the performance of short-term in vivo assays, and the relevance of devising separate strategies to test for possible carcinogens and germ cell mutagenicity.
A prospective toxicity evaluation (COMPACT) on 40 chemicals currently being tested by the National Toxicology Program.
The computer-optimized molecular parametric analysis of chemical toxicity (COMPACT) procedure has been used to determine the molecular conformation and electronic structure of a series of 40 chemicals and predicted the absence of toxicity in four chemicals considered to be potentially genotoxic.
Regulation of food-related carcinogens in Japan.
  • S. Sato
  • Chemistry, Medicine
    Regulatory toxicology and pharmacology : RTP
  • 1990